The combination of selective inhibition of the cannabinoid CB1 receptor and activation of the cannabinoid CB2 receptor yields improved attenuation of motor and autonomic deficits in a mouse model of spinal cord injury.
Heller
Joshua E
JE
Department of Neurosurgery, Temple University Hospital, Pittsburgh, Pennsylvania, USA.
Baty
Darric E
DE
Zhang
Ming
M
Li
Hongbo
H
Adler
Martin
M
Ganea
Doina
D
Gaughan
John
J
Loftus
Christopher M
CM
Jallo
Jack I
JI
Tuma
Ronald F
RF
D000818:Animals; D001341:Autonomic Nervous System / Q000187:drug effects*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D051379:Mice; D008810:Mice, Inbred C57BL; D009043:Motor Activity / Q000187:drug effects*; D010880:Piperidines / Q000008:administration & dosage*; D011720:Pyrazoles / Q000008:administration & dosage*; D043884:Receptor, Cannabinoid, CB1 / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D043885:Receptor, Cannabinoid, CB2 / Q000008:administration & dosage / Q000819:agonists*; D000077285:Rimonabant; D013119:Spinal Cord Injuries / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*; D001743:Urinary Bladder / Q000187:drug effects / Q000503:physiopathology
D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D000077285:Rimonabant